Exchange: NASDAQ·Updated 06:10 PM EDT

HALO News

News
all
press releases
Halozyme Announces Appointment of Jim Daly to its Board of Directors
Halozyme Announces Appointment of Jim Daly to its Board of Directors Halozyme Announces Appointment of Jim Daly to its Board of DirectorsPR NewswireSAN DIEGO, Sept. 30, 2026SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today...
PR Newswire
Halozyme Announces Appointment of Jim Daly to its Board of Directors
Halozyme Announces Appointment of Jim Daly to its Board of Directors Halozyme Announces Appointment of Jim Daly to its Board of DirectorsPR NewswireSAN DIEGO, Sept. 30, 2026SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today...
PR Newswire
More News
HALO May 2027 Options Begin Trading
Investors in Halozyme Therapeutics Inc (Symbol: HALO) saw new options become available today, for the May 2027 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly avail...
Nasdaq News: Markets
Why Women-Run Companies Deserve a Place in Your Portfolio
BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
Zacks
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. FTNT, ABBNY, EAT and HALO are some such stocks.
Zacks
$1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today
Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 15 years by 8.16% on an annualized basis producing an average annual return of 21.6%. Currently, Halozyme Therapeutics has a marketread more...
Benzinga
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Zacks
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
Zacks
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033PR NewswireSAN DIEGO, Sept. 17, 2026 SAN...
PR Newswire
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033PR NewswireSAN DIEGO, Sept. 16, 2026 SAN DIEGO, Sept. 16, 2026 /PRNewswire...
PR Newswire

Advertisement|Remove ads.